Overview: Genodermatoses Sequencing TestIntroduction: The Genodermatoses Sequencing Test sequences the exome to diagnose genetic skin disorders, causing rashes or skin fragility. Aligned with 2023 AAD guidelines, it uses PCR for high specificity, aiding in genetic screening. This test is critical for guiding diagnosis, management, and improving outcomes in molecular pathology for patients with suspected genetic skin disorders.
Other Names: Genodermatoses Exome Assay, Genetic Skin Disorder Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Genodermatoses sequencing began in the 2000s with genetic research. Exome sequencing emerged in the 2010s, improving accuracy for skin disorder diagnosis.
Purpose: Diagnoses genetic skin disorders, guides management, and monitors exome mutations in patients with rashes or skin fragility.
Test Parameters: 1. Exome Sequencing
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva at any time. Report symptoms like rashes or skin fragility, and list family history.
Specimen: 2-5 mL whole blood (EDTA), 1-2 buccal swabs (sterile swab), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document rashes, skin fragility, or family history of genetic skin disorders. Include current medications or skin treatments.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for genetic counseling.
Procedural Considerations: Uses PCR-based exome sequencing to detect mutations. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Low DNA yield or contamination can affect results. Rare mutations may require additional analysis.
Clinical Significance: Identified mutations confirm genetic skin disorders, guiding management. Negative results may require targeted testing.
Specialist Consultation: Consult a dermatologist or geneticist for result interpretation.
Additional Supporting Tests: Skin biopsy, targeted gene panels, or clinical evaluations to confirm genodermatoses.
Test Limitations: Variants of unknown significance may complicate interpretation. Results require clinical correlation.
References: AAD Genodermatoses Guidelines, 2023; Journal of Investigative Dermatology, Uitto J, 2022.
